A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes
Status:
Completed
Trial end date:
1998-01-01
Target enrollment:
Participant gender:
Summary
To determine whether alternating oral ganciclovir with intravenous ( IV ) ganciclovir can
prevent relapse of Cytomegalovirus ( CMV ) retinitis and improve quality of life in AIDS
patients.
A systemic treatment strategy for CMV retinitis is needed that will be effective yet
convenient to administer, without the need for a permanent indwelling IV catheter. Although
oral ganciclovir has been used as maintenance following induction with IV ganciclovir,
patients with reactivation of disease must be reinduced IV. A fixed-schedule regimen in which
oral and IV ganciclovir are alternated may prevent reactivation and progression of disease,
as opposed to the current therapeutic strategy in which changes in therapy are event-driven.
Also, the duration of intermittent IV therapy required to control disease may be short enough
to eliminate the need for an indwelling catheter.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)